Clinical Trial Update: Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing APX005M with gemcitabine and nab-paclitaxel, with or without nivolumab, in previously untreated metastatic pancreatic adenocarcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• APX005M
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• nivolumab (nivolumab)

Snippet

Sponsor: Parker Institute for Cancer Immunotherapy | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-11